Aroa Biosurgery Past Earnings Performance

Past criteria checks 0/6

Aroa Biosurgery has been growing earnings at an average annual rate of 18.8%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 41.4% per year.

Key information

18.8%

Earnings growth rate

85.4%

EPS growth rate

Biotechs Industry Growth9.6%
Revenue growth rate41.4%
Return on equity-8.5%
Net Margin-12.6%
Last Earnings Update30 Sep 2023

Recent past performance updates

Recent updates

Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation

Mar 25
Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation

Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge

Jan 30
Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge

Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors

Nov 14
Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors

Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts

Nov 02
Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts

Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price

Oct 25
Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price

We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth

May 13
We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth

Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results

May 26
Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results

An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued

Mar 22
An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued

Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?

Feb 24
Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?

Don't Ignore The Fact That This Insider Just Sold Some Shares In Aroa Biosurgery Limited (ASX:ARX)

Feb 24
Don't Ignore The Fact That This Insider Just Sold Some Shares In Aroa Biosurgery Limited (ASX:ARX)

Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 44% Above Its Share Price

Dec 16
Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 44% Above Its Share Price

Revenue & Expenses Breakdown
Beta

How Aroa Biosurgery makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:ARX Revenue, expenses and earnings (NZD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2366-85610
30 Jun 2365-45210
31 Mar 236304811
31 Dec 2257-14211
30 Sep 2251-23711
30 Jun 2245-53410
31 Mar 2240-8318
31 Dec 2135-10288
30 Sep 2131-11267
30 Jun 2127-15247
31 Mar 2122-19226
31 Dec 2022-19216
30 Sep 2021-19205
30 Jun 2023-12185
31 Mar 2025-6175
31 Mar 19241125
31 Mar 1811-143

Quality Earnings: ARX is currently unprofitable.

Growing Profit Margin: ARX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ARX is unprofitable, but has reduced losses over the past 5 years at a rate of 18.8% per year.

Accelerating Growth: Unable to compare ARX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ARX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-9.3%).


Return on Equity

High ROE: ARX has a negative Return on Equity (-8.53%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.